中國同輻(01763.HK)與秦山核電站聯合研發的C-14碳酸鋇產品進軍歐美市場
格隆匯6月30日丨中國同輻(01763.HK)發佈公告,近日,在第15屆國際同位素標記化合物合成與應用研討會上,中國同輻與秦山核電站聯合研發的C-14碳酸鋇產品驚豔亮相,並與英國、瑞士、德國等國家的行業領軍企業達成多項銷售合作備忘錄及銷售協議,是我國堆產醫用同位素首次實現批量化出口。
作爲放射性標記技術的核心原料,C-14碳酸鋇廣泛應用於藥代動力學研究、幽門螺桿菌檢測(尿素呼氣試驗)、農藥代謝分析等關鍵領域。此前,該產品的製備技術長期被國際少數企業掌控。中國同輻與秦山核電站聯合經過多年技術攻關,成功研發生產出C-14碳酸鋇,各項指標均達到國際先進水準。
未來,中國同輻將繼續深化國際合作,以創新驅動發展,讓更多“中國創造”的核技術應用產品服務全球市場,書寫中國高端製造出海的新篇章。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.